1-3 of 3
Olivier Demaria
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Preclinical Characterization of Antitumor Activity of IPH6501, a First-in-Class IL2v-Armed Tetraspecific NK Cell Engager Directed Against CD20, and Comparison with Approved CD20-Targeting Therapies

Free
Florent Carrette, Olivier Demaria, William Baron, Marilyn Giordano, Nourhène Belaid, Jean-Baptiste Vallier, Sylvia Trichard, Manon Clemenceau, Mathilde Girard-Madoux, Marie Vétizou, Romain Remark, Marie-Laure Thibult, Caroline Denis, Pascale Andre, Cécile Bonnafous, Ariane Morel, Nicola Beltraminelli, Yannis Morel, Carine Paturel, Eric Vivier
Journal: Blood
Blood (2024) 144 (Supplement 1): 5824.
https://doi.org/10.1182/blood-2024-201502
Published: 2024
Journal Articles

IPH6501 Is a Novel NKp46-Targeting Tetraspecific Antibody-Based Natural Killer Cell Engager Therapeutic (ANKET) Armed with a Non-Alpha IL-2 Variant and Developed for the Treatment of CD20-Positive Malignancies

Free
Olivier Demaria, Guillaume Habif, François Le Floch, Laura Chiossone, Romain Remark, Marie Vetizou, Nadia Maurel, Laurent Gauthier, Yannis Morel, Carine Paturel, Eric Vivier, Pascale Andre
Journal: Blood
Blood (2022) 140 (Supplement 1): 11559.
https://doi.org/10.1182/blood-2022-163561
Published: 2022
Journal Articles

Impairment of both IRE1 expression and XBP1 activation is a hallmark of GCB DLBCL and contributes to tumor growth

Free
Bojan Bujisic, Aude De Gassart, Rémy Tallant, Olivier Demaria, Léa Zaffalon, Sonia Chelbi, Michel Gilliet, Francesco Bertoni, Fabio Martinon
Journal: Blood
Blood (2017) 129 (17): 2420–2428.
https://doi.org/10.1182/blood-2016-09-741348
Published: 2017
Includes: Supplemental data